Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Sepulveda AR1, Hamilton SR2, Allegra CJ3, Grody W4, Cushman-Vokoun AM5, Funkhouser WK6, Kopetz SE7, Lieu C8, Lindor NM9, Minsky BD10, Monzon FA11, Sargent DJ12, Singh VM13, Willis J14, Clark J15, Colasacco C16, Bryan Rumble R17, Temple-Smolkin R18, B Ventura C16, Nowak JA19.

Author information

Abstract

OBJECTIVES:

-To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens.

METHODS:

-The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted.

RESULTS:

-Twenty-one guideline statements were established.

CONCLUSIONS:

-Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.

PMID:: 28165284
DOI:: 10.5858/arpa.2016-0554-CP

Specific PHGKB|Cancer|PHGKB

Colorectal Cancer Genomics

- Cancer PHGKB -

From Guideline Database

This database contains updated guidelines, policies and recommendations on genomic research and practice, as provided by professional organizations, federal advisory groups, expert panels and policy groups.